Transthyretin variants
AssigneeAmgen Inc.
InventorsKenneth W. WALKER, Fei XIONG
Life of this patent
Estimating the term…
Abstract
The present invention provides a means for increasing the serum half-life of a selected biologically active agent by utilizing transthyretin (TTR) as a fusion partner with a biologically active agent. Specifically, the present invention provides substantially homogenous preparations of TTR (or a TTR variant)-biologically active agent fusions and PEG-TTR (PEG-TTR variant)-biologically active agent fusions. As compared to the biologically active agent alone, the TTR-biologically active agent fusion and/or PEG-TTR-biologically active agent fusion has substantially increased serum half-life.
Claims14
A nucleic acid encoding a transthyretin (TTR) variant comprising the amino acid sequence as set forth in SEQ ID NO:1 having two to three amino acid substitutions, wherein the cysteine at position 10 and the lysine at position 15 of SEQ ID NO:1 are substituted for another amino acid.
-8. (canceled)
-13. (canceled)
A nucleic acid encoding a fusion protein, said fusion protein comprising a biologically active protein fused to a TTR variant comprising the amino acid sequence as set forth in SEQ ID NO:1 having two to three amino acid substitutions, wherein the cysteine at position 10 and the lysine at position 15 of SEQ ID NO:1 are substituted for another amino acid, and wherein said fusion protein has a longer half-life in serum than the biologically active protein lacking the TTR variant.
-16. (canceled)
-20. (canceled)
Dependencies are inferred from the claim text.